New antibody treatment for bacterial pneumonia
Bacterial Pneumonia Therapeutic Antibody Safety Trial
['FUNDING_OTHER'] · TRELLIS BIOSCIENCE, INC. · NIH-10918359
This study is testing a new treatment called TRL1068 to see if it can help people with prosthetic joint infections by breaking down tough bacteria that resist antibiotics, making the antibiotics work better.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TRELLIS BIOSCIENCE, INC. (nih funded) |
| Locations | 1 site (Redwood City, UNITED STATES) |
| Trial ID | NIH-10918359 on ClinicalTrials.gov |
What this research studies
This research investigates a novel human monoclonal antibody called TRL1068, which aims to disrupt biofilms formed by bacteria that contribute to antibiotic resistance in bacterial pneumonia. The study focuses on enhancing the effectiveness of conventional antibiotics by using TRL1068 to target biofilm-associated bacteria, which are known to be significantly less sensitive to antibiotics. Patients with prosthetic joint infections will be treated with this antibody to assess its safety and efficacy in reducing bacterial burden. The research includes a clinical trial where patient outcomes will be closely monitored to evaluate the treatment's impact.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults with prosthetic joint infections who are experiencing complications due to bacterial biofilms.
Not a fit: Patients without prosthetic implants or those who do not have bacterial pneumonia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for bacterial pneumonia and related infections, potentially reducing the need for invasive procedures.
How similar studies have performed: Previous studies have shown promising results with similar monoclonal antibody approaches in treating biofilm-related infections, indicating potential for success in this research.
Where this research is happening
Redwood City, UNITED STATES
- TRELLIS BIOSCIENCE, INC. — Redwood City, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KAUVAR, LAWRENCE MICHAEL — TRELLIS BIOSCIENCE, INC.
- Study coordinator: KAUVAR, LAWRENCE MICHAEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.